research COVID-19 clinical outcomes and nationality: results from a Nationwide registry in Kuwait
Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.
Search
for
Sort by
Research
990-1000 / 1000+ results research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Collider bias undermines our understanding of COVID-19 disease risk and severity
Collider bias can mislead our understanding of COVID-19 risk and severity.
research Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines
Androgen measurement helps diagnose PCOS, but accuracy varies, needing standard methods.
research Quality of life in patients with scarring and non‐scarring alopecia: An exploratory cross‐sectional study
Hair loss negatively impacts quality of life, and psychological support can help.
research Prevalence of polycystic ovary syndrome under NIH criteria among the tenth-grade Chinese schoolgirls in Guangzhou area: a cross-sectional epidemiological survey
Polycystic Ovary Syndrome (PCOS) was found in 3.86% of tenth-grade girls in Guangzhou, China, with higher rates in overweight and obese girls, suggesting diagnosis should focus on hyperandrogenemia.
research High-throughput and direct measurement of androgen levels using turbulent flow chromatography liquid chromatography-triple quadrupole mass spectrometry (TFC-LC-TQMS) to discover chemicals that modulate dihydrotestosterone production in human prostate cancer cells
Researchers found four natural compounds that can change DHT levels in prostate cancer cells.
research Toluene Diisocyanate (TDI) Disposition and Co-Localization of Immune Cells in Hair Follicles
Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.
research 085 Coordinate expressions of cyclin-dependent kinase inhibitors and high sulfur protein in human hair follicles
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
This study evaluated the 28-week effectiveness and safety of tralokinumab in 84 adult patients with moderate-to-severe atopic dermatitis (AD). The treatment significantly improved clinical outcomes, with 75.8% achieving an Eczema Area and Severity Index (EASI) of ≤7 and 51.4% achieving a numerical rating scale (NRS) for pruritus of ≤4. Serum proteins associated with disease severity decreased, and total IgE levels significantly decreased in dupilumab-naïve patients. However, 27.4% of patients discontinued treatment due to adverse events or ineffectiveness, with hair loss being the most common reason for discontinuation. Overall, tralokinumab proved effective for both dupilumab-naïve and non-naïve patients, with clinical improvements supported by biological data.